Bolder BioTechnology has a diversified pipeline of proprietary, long-acting human protein pharmaceuticals that include potential treatments for hematological and endocrine disorders, cancer and infectious disease. These products target markets with over $20 billion in annual sales and have clearly defined clinical development paths, which will allow them to be developed cost-effectively. We believe the more convenient dosing schedules, superior efficacy and improved safety of our products will make them attractive to patients and allow our products to capture a significant portion of these lucrative markets. Our most advanced research programs are described below.
|Clinical Indication||Program||Research||Preclinical||Phase 1||Phase 2||Phase 3|